Genetic platforms: Do we do what we know? or do we know what we do? Laia Bernet; María Jesús Pla; Noelia Martinez Jañez;

Can we use HER2DX to modulate treatment intensity in HER2 positive early breast cancer? Beatriz Alonso De Castro; Cristina Reboredo Rendo; Fernanda Mosele; Lopez; Martinez; Silvia Antolín Novoa;

The role of artificial intelligence integrating multi-omics in breast cancer Gomez-Bravo; Benjamín Walbaum; Elia Segui; Munoz;